Nanostructured recombinant cytokines: A highly stable alternative to short-lived prophylactics

Débora Torrealba, David Parra, Joaquin Seras-Franzoso, Eva Vallejos-Vidal, Daniel Yero, Isidre Gibert, Antonio Villaverde, Elena Garcia-Fruitós, Nerea Roher

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)


© 2016 Elsevier Ltd Cytokines have been widely used as adjuvants and therapeutic agents in treatments of human diseases. Despite their recognized potential as drugs, the medical use of cytokines has considerable drawbacks, mainly related to their low stability and short half-life. Such intrinsic limitations imply the administration of high doses, often prompting toxicity, undesirable side effects and greater production costs. Here, we describe a new category of mechanically stable nanostructured cytokines (TNFα and CCL4/MIP-1β) that resist harsh physicochemical conditions in vitro (pH and temperature), while maintaining functionality. These bio-functional materials are produced in recombinant cell factories through cost-effective and fully scalable processes. Notably, we demonstrate their prophylactic potential in vivo showing they protect zebrafish from a lethal infection by Pseudomonas aeruginosa.
Original languageEnglish
Pages (from-to)102-114
Publication statusPublished - 1 Nov 2016


  • Cytokines
  • Immunization
  • Inclusion bodies
  • Macrophages
  • Nanoparticles
  • Zebrafish


Dive into the research topics of 'Nanostructured recombinant cytokines: A highly stable alternative to short-lived prophylactics'. Together they form a unique fingerprint.

Cite this